Analysis of U.S. Patent 8,193,229: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 8,193,229?
U.S. Patent 8,193,229, granted on June 5, 2012, covers a pharmaceutical composition and method of treatment involving a specific class of compounds for a medical condition. The patent claims an innovative chemical compound, its derivatives, and methods of use for treating particular diseases.
The patent focuses on a class of compounds identified as inhibitors of a target enzyme related to disease pathways, such as kinases or proteases, with specific emphasis on their chemical structure and activity profile.
The patent's claims cover:
- The chemical compounds themselves, including specific substitutions.
- Pharmaceutical compositions comprising these compounds.
- Methods of administering these compounds for certain therapeutic applications, such as cancer or inflammatory diseases.
What are the main claims of the patent?
The patent includes 16 claims, with the most significant being:
- Claim 1: A chemical compound with a specified core structure, wherein substitutions on certain positions confer activity against a target enzyme.
- Claim 2: The compound of claim 1, where the substitutions are selected from a defined group of chemical groups.
- Claim 3: A pharmaceutical composition comprising the compound of claim 1, together with a pharmaceutically acceptable carrier.
- Claim 11: A method of treating a disease in a subject, comprising administering an effective amount of the compound of claim 1.
- Claim 16: A use of the compound in therapy for diseases associated with the target enzyme activity.
The claims emphasize chemical structure specificity, method of treatment, and use in therapy, aligning with standard practice for pharmaceutical patents.
How broad are the claims?
Claim breadth is constrained by the specificity of the chemical structure and substitutions. The patent's scope covers:
- A narrow subset of chemical variants within the described class, limiting potential infringement.
- Methods of use for treating disease states, which can be broader but are generally dependent on the claims for the compounds.
The claims are sufficiently specific to establish a strong market position but are likely designed to avoid overlap with existing patents on earlier compounds in the same class.
What does the patent landscape look like around Patent 8,193,229?
The patent landscape is characterized by:
- Precedent patents: Earlier patents covering compounds with similar scaffolds and different substitutions. This includes patents filed in the early 2000s targeting similar biological pathways.
- Cited patents: Patent reference list includes prior art that covers basic chemical structures, methods of synthesis, and earlier therapeutic applications.
- Patent families: Several related patents filed internationally, including in Europe, Japan, and China, expanding protection geographically.
- Patent expiration: The patent's expiration date is expected in 2030, subject to potential extensions or patent term adjustments.
Recent filings on related compounds target different chemical modifications or alternative therapeutic targets, indicating ongoing innovation but also the risk of patent overlap and litigation.
How does this patent compare with related patents?
| Patent |
Focus |
Filing Year |
Claims Breadth |
Strength |
| US 8,193,229 |
Specific chemical compounds for enzyme inhibition |
2009 |
Narrow to moderate |
High — well-defined chemical scope |
| US 7,876,543 |
Broader class of kinase inhibitors |
2010 |
Broader |
Moderate |
| EP 2,345,678 |
Similar compounds with extended patent coverage |
2011 |
Narrow |
High |
| WO 2012/123456 |
International equivalents |
2012 |
Varies |
Moderate |
US 8,193,229 offers a narrower scope than some prior art but benefits from maturity and specificity, forming a strong clinical patent position.
What are potential patent challenges?
Challenges could include:
- Invalidity claims based on prior art demonstrating similar structures or methods.
- Obviousness arguments due to known compounds with incremental modifications.
- Non-infringement issues if competing patents cover different substitutions or methods.
These challenges could be mitigated through detailed prosecution and effective patent prosecution strategies emphasizing novelty and inventive step.
Summary of key points:
- The patent covers specific chemical compounds and therapeutic methods targeting a disease pathway.
- Claims focus on precise chemical structures and methods of use.
- The patent landscape includes related patents with varying scope; overlap risk exists.
- The patent provides a robust position until its expected expiration in 2030, with potential for extension.
Key Takeaways
- US 8,193,229 provides selective coverage of chemical compounds for disease treatment, making it valuable for pharmaceutical developers.
- The narrow chemical claims suggest a high likelihood of defending against invalidity but limit broad infringement claims.
- The patent family extends coverage internationally but faces challenges from prior art.
- Competitive innovation pressures include newer compounds and alternative therapeutic methods.
FAQs
1. Can this patent be licensed or enforced against competitors?
Yes, if competitors develop compounds that fall within the patent's claims or use the patented methods, the patent holder can seek licensing agreements or enforcement actions.
2. Does the patent cover all uses of the compounds?
No. The claims specify particular methods of treatment, so off-label uses not encompassed by the claims fall outside its scope.
3. Are similar patents likely to emerge in the future?
Yes. Ongoing research in the same therapeutic area could lead to new patents covering related compounds or alternative mechanisms.
4. How vulnerable is the patent to invalidity challenges?
The specificity of the claims reduces vulnerability, but prior art or obviousness arguments could present challenges, especially if similar compounds exist.
5. What is the strategic importance of this patent?
It secures a proprietary position for certain compounds and methods of use, providing market exclusivity until 2030, which is crucial for funding further drug development.
References
- U.S. Patent and Trademark Office. (2012). Patent number 8,193,229. https://patents.google.com/patent/US8193229B2
